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Summary Recurrent pleural malignant effusion is a common problem which can be
treated by inducing symphysis of the pleural sheets. Many different drugs
administered into the pleural space can be used to achieve this. The drugs cause
an inflammatory response, which in turn is believed to cause the symphysis.
Comparatively little has been published on the degree of pleural inflammation and
the systemic response and whether this will affect the outcome.
The aim of this study was to describe the systemic inflammatory reaction following
instillation of a chemical agent into the pleura and to investigate whether this had
any predictive value for the outcome (i.e. the pleurodesis). The markers
investigated were simple ones: erythrocyte sedimentation rate, C-reactive protein,
and leukocyte count from venous blood samples, and the fever reaction.
Eighty-nine prospective patients with malignant pleural effusion who underwent
pleurodesis with either talc (48 patients) or quinacrine (41 patients) were included
in the study. Symphysis was achieved in 82 patients (92 per cent) and all had a
prominent transitional elevation of the inflammatory parameters. The unsuccessful
attempts caused negligible or very small elevations, but due to the small numbers
only the degree of fever after 8 and 48 h showed a statistically significant difference.
In conclusion, pleurodesis causes a systemic inflammation and there is a tendency
to a correlation between the success of pleurodesis and the degree of inflammation.
High fever and high inflammatory parameters including CRP are due to this
inflammatory response and do not indicate infection.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The aim of pleurodesis in recurrent pleural effu-
sions is a symphysis of the pleural sheets, thereby
preventing further accumulation of fluid. The
primary indication for pleurodesis is recurrent
fluid accumulation in the pleural space requiring
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repeated thoracocentesis for relief of symptoms.
This is commonly seen in malignant effusions. For a
pleurodesis to be attempted, the patients should
be in a not too bad general condition, have a
reasonably long life expectancy, and have shown a
poor response to systemic treatment.
Pleurodesis is achieved by the induction of an
inflammatory process in the pleural space, trig-
gered by intrapleural instillation of a reactive agent
or by mechanical injury to the pleura. A variety of
agents have been used to achieve pleurodesis.1
Several studies have investigated the inflammatory
response at the local level, i.e. in the pleura, both
in animal experiments and in humans. The dom-
inating cell at the primary acute phase is the
leukocyte.2 The detailed mechanisms have, how-
ever, not been elucidated. Nor have the acute
systemic reactions of simple inflammatory para-
meters, such as fever and basic biochemical
markers like erythrocyte sedimentation rate
(ESR), leukocyte cells, and C-reactive protein
(CRP), been well described in the literature.
Furthermore, there is no firm proof that the
intensity of the acute inflammation is a predictor
for the outcome of the pleurodesis attempt.
At the Lung Department of Karolinska Hospital,
Sweden, a large number of patients are treated
with pleurodesis every year. For some decades,
quinacrine has been used for this,2 and during the
last few years talc has also been tried. Both agents
are excellent sclerosing agents, and there is no
statistical significant difference between the two
drugs on the overall outcome.3
The aim of the present study was to describe the
acute systemic inflammatory reaction, using such
simple parameters as fever reaction and basic
biochemical markers, in order to present ‘‘normal
values’’ for the procedure, and to correlate them
with the outcome of pleurodesis. In addition, the
pleural fluid glucose and pH were measured, since
these factors have been described as predictors of
success.
Patients and methods
Patients
Eighty-nine consecutive patients, 51 men 38 wo-
men, were included in the study. Their mean age
was 67711 years. All had malignant pleurisy
confirmed by biopsy and had undergone repeated
thoracocentesis before pleurodesis. The most
common primary was bronchial carcinoma (29
patients), 15 had mammary carcinoma, another
15 malignant mesothelioma, and two had a
lymphatic tumour. Fourteen had some other known
primary tumour and another 14 adenocarcinoma-
tosis of the pleura with unknown primary origin.
None had previously had attempts at pleurodesis
nor intrapleural instillation of any other kind. They
were all judged to benefit from pleurodesis based
on subjective improvement of dyspnea after earlier
thoracocentesis and had a performance status of 0–
3 according to the WHO scale.4 Patients with
trapped lungs and/or with a short life expectancy
were excluded. All patients gave informed consent.
The study was approved by the local ethics
committee.
Methods
All patients underwent thoracocentesis at which
500–1000ml fluid was evacuated and 400–700ml
room air installed. To enable evaluation of the
pleural space, a medical thoracoscopy was per-
formed in local anesthesia using a rigid thoraco-
scope of 7.5mm diameter and 43 cm length (Karl
Storz-Endoscope, Germany). After biopsies to con-
firm the diagnosis, a chest tube of 0.50m length
and a width of 6.7mm (Sherwood Medical, Tulla-
more, Ireland) was inserted and suction of 15 to
20 cm water was applied. Chest roentgenograms
were taken the following days, and when the lung
had expanded sufficiently to make a pleurodesis
possible the patients received the sclerosing agent
via the tube.
Treatment
Five grams of asbestos-free and sterile packed
talcum with the mean size of 10 mm and with 25 per
cent less than 5 mm (Luzenac Pharma, Val Chisone
S.P.A., Via Nazionale, Italy) or 500mg of Mepacrin/
quinacrine (Vipor Chemical, Baroda, India) dis-
persed in 200ml of isotone saline solution was
instilled through the tube. The drainage tube was
clamped for 2 h after which suction was once again
applied. The daily fluid production was measured,
and when it was less than 50ml/24 h the tube was
removed. If after 72 h from drug instillation the
fluid production was still more than 50ml/24 h,
treatment was repeated. If after another 72 h fluid
production was still more than 50ml/24 h, the
pleurodesis was considered to be a failure.
pH and glucose in the pleural fluid
Pleural fluid pH was measured immediately using a
blood gas analyzer (IRMA blood analysis system,
ARTICLE IN PRESS
Inflammatory after pleurodesis 1167
Diametrics Medical, Inc. St. Paul, MN, USA) and the
levels of glucose in the pleural fluid and in the
serum were each measured within 30min of the
thoracocentesis.
Inflammatory parameters
Body temperature was measured four, eight, and at
every 12 h after instillation of the drug, and venous
blood samples for analysis of ESR, CRP, and
leukocyte count were acquired every 24 h until
the drainage tube had been removed.
Statistical analysis
Mixed linear models were used for analysing the
interaction of outcome *time on CRP, leukocyte
count, ESR and temperature. The data are reported
as the mean7SD unless otherwise noted. Spearman
Rank correlation was used for non-numeric vari-
ables and w2 test was used to determine the
correlation between outcome and inflammation
parameters. Differences between outcome groups
were tested by t-test. Statistical analyses were
preformed using SAS 8.2 and SPSS 11.5. STATISTICA
6.1 preformed graphical presentations.
Results
Pleurodesis (i.e. fluid production less than 50ml/
24 h) was achieved in 72 patients (81 per cent)
within the first 72 h. Thus, 17 patients (19 per cent)
needed a second instillation, and in twelve of them
pleurodesis was achieved. Thus, treatment was
unsuccessful in only seven patients (8 per cent).
There were no differences with regard to the
presence of tumour involvement, nor sizes, adher-
ences or thickening of the pleural sheets, as
observed at thoracoscopy with the inflammatory
parameters measured.
Fever reaction
Fever was the rule, with the maximum at 8 h after
instillation and starting to decline at about the
36 h, and occurred in all patients in whom
symphysis of the pleural sheets was achieved. The
mean body temperature value was 38.071.01C
with a maximum of 40.21C. The failures had their
maximum mean temperature of 37.770.61C at 24 h
after administration (Table 1, Fig. 1). Thus, the
higher the fever reaction, the greater the chances
for success, but the overall statistical test showed a
non-significant interaction between fever reaction
and outcome, P ¼ 0:30: There was, however, a
significant difference in the mean values of
temperature between success and failures at 8
(P ¼ 0:03) and 48 h (P ¼ 0:04).
Erythrocyte sedimentation rate (ESR)
The mean ESR value at baseline was 30722mm/h
for patients with successful sclerosis and 54727 for
failures at first attempt (P ¼ 0:04) . The increase
after treatment was between 30 and 250 per cent
compared to the baseline. The rise could be seen
already at 24 h and reached its maximum at 72 h
post instillation. The mean values at 72 h were
64723 and 61717mm/h for success and failures,
respectively (Table 1, Fig. 2). Patients that re-
ceived a second instillation of the drug had then a
comparatively moderate elevation of 3–70 per
cent; only three patients with successful pleurod-
esis had a negligible elevation of less than 10 per
cent.
C-reactive protein (CRP)
The range of CRP at the baseline was 7–207mg/l,
with a mean value of 34738 for those who later
had a successful sclerosis and 47720 for those who
failed and increased in most patients with a
maximum after 48 h. At baseline the ‘‘failures’’
had a higher CRP, but at all other times the
‘‘successes’’ had higher values, though not statis-
tically significant (Table 1, Fig. 3). There was no
statistical difference on the outcome (P ¼ 0:57).
Leukocyte count
The leukocyte count was the same for both groups
at baseline and also increased after instillation.
The highest mean value for patients who achieved
symphysis was 13.9 109/l and for failures 11.8
(Table 1, Fig. 4). The highest value observed at all
four measuring time points was in one patient who
had leukaemia. However, the increase in percen-
tage was comparable to the majority of the other
patients, with a baseline value of 36.4 109/l and a
peak of 41.7 109/l.
Pleural fluid glucose
The non-fasting values of glucose in the pleural
fluid ranged from 1.1 to 15.3mmol/l while the
range of blood glucose was 4.3–17.1mmol/l. There
was no difference between those who succeeded
and the failures (Table 1). The highest values in
both the pleural fluid and blood were noted on the
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same patient, who was a diabetic. Twenty per cent
of the patients had similar values in the pleural
fluid and in the blood, otherwise the level of blood
glucose was generally higher than that of the
pleural fluid. There was no correlation between
initial pleural fluid glucose level and temperature,
fluid accumulation, ESR or leukocyte count, but a
positive correlation was observed in CRP after 48 h
(P ¼ 0:002 ) and 72 h (P ¼ 0:000) after instillation.
Pleural fluid pH values
The majority (82 per cent) of the patients had
levels of pleural fluid pH range of 7.3–7.5 while 15
per cent had a range of 7.6–8.5 and 3 per cent
7.25–5.0. These values had no correlation to the
degree of tumour invasion of the pleural space or to
the values of pleural fluid glucose, ESR, CRP, or
leukocyte counts, nor to the outcome of pleural
symphysis.
Discussion
The aim of pleurodesis is to prevent recurrent
accumulation of pleural fluid and thereby achieve
relief of dyspnea. It involves some temporary
discomfort as a result of the inflammation provoked
by the instillation of the drug. The inflammatory
reaction is regarded as an important factor for
achieving the goal, i.e. a symphysis of the pleural
layers. Some studies have been made on the local
inflammation evoked by various agents adminis-
tered into the pleural space.2,5,6 Studies of
some cytokines (interleukin and tumour necrosis
factor) of pleural effusions have shown that such
factors are involved and have some diagnostic and
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Table 1 Initial pleural fluid glucose level and pH, and inflammatory parameters with successful and unsuccessful
pleurodesis at first attempt.
Variables Time (h) Successful symphysis
(mean7SD)
Unsuccessful symphysis
(mean7SD)
P-value
Temperature (1C) 4 37.470.8 36.870.5 0.10
8 38.071.0 37.070.5 0.02
12 37.970.8 37.770.8 0.52
24 37.670.8 37.770.6 0.63
36 37.870.8 37.470.8 0.24
48 37.370.8 36.670.6 0.03
60 37.670.8 36.970.6 0.05
72 37.070.8 36.870.7 0.52
ESR (mm/h) Baseline 30722 54727 0.04
24 37721 42720 0.55
48 55722 53719 0.85
72 64724 61717 0.77
Mean maximal increase 34 (72 h) 7 (72 h)
CRP (mg/l ) Baseline 34738 47720 0.44
24 133780 94765 0.23
48 2527103 199779 0.19
72 2147106 174757 0.33
Mean maximal increase 228 (48 h) 152 (48 h)
Leukocyte ( 109) Baseline 7.874.1 7.872.9 0.96
24 13.974.9 11.374.0 0.20
48 12.475.0 11.873.9 0.76
72 9.874.0 9.873.5 0.96
Mean maximal increase 6.1 (24 h) 4.0 (48 h)
Pleural fluid glucose
(mmol/l)
5.3472.57 3.0671.54 0.05
Pleural fluid pH 7.5270.35 7.6470.58 0.52
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prognostic value.2,7 However, comparatively little
has been written on the systemic inflammatory
response, i.e. the fever reaction and the inflam-
matory parameters in the blood.
The major objective of this study was to describe
the evaluation of basic inflammatory parameters such
as ESR, CRP, leukocytes, and fever reaction induced
by pleurodesis. We found that these basic biochem-
ical factors were elevated in the treated patients,
and that the elevations were temporary and sponta-
neously normalised. There were no significant differ-
ences with regard to the presence of tumour
involvement nor sizes, adherences or thickening of
the pleural sheets as observed at thoracoscopy.
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Figure 1 Time course of intrapleural drug instillation on fever reaction (centigrade) in successful and unsuccessful
symphysis. The main effect of time* outcome interaction was statistically non-significant, P ¼ 0:30:
Figure 2 Time course of intrapleural drug instillation on ESR (mm) to treatment outcome. The main effect of time*
outcome interaction was statistically non-significant, P ¼ 0:25:
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From the literature, it can be seen that a fever
reaction occurs after 4–12 h following talc instilla-
tion and may last for 72 h.8 In about 10 per cent
it is higher than 38.51C.9 In a large French study, 66
per cent had fever.10 Fever can be induced by
several causes, for example infection, inflamma-
tion, malignancy, or various toxins. It is caused by
exogenous pyrogens and/or pyrogenic cytokines.
Cytokines such as interleukin-6, interleukin-1a and
-1b, tumour necrosis factor a and g; can induce
fever reactions following intrapleural drug instilla-
tion. It is logical that their levels mirror the
intensity of the inflammation and also the degree
of fever. Although an elevated level of CRP is not
always associated with fever, a febrile reaction is
generally associated with a rise in CRP. The
elevated level of CRP then activates the comple-
ment system.11
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Figure 4 Time course of intrapleural drug instillation on Leukocyte count ( 109/l) to treatment outcome. The main
effect of time* outcome interaction was statistically non-significant, P ¼ 0:72:
Figure 3 Time course of intrapleural drug instillation on C-reactive protein (mg/l) to treatment outcome. The main
effect of time* outcome interaction was statistically non-significant, P ¼ 0:57:
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In the present study, none of the patients had para-
malignant fever prior to pleurodesis, nor persisting or
prolonged fever post pleurodesis, indicating that the
fever reaction was as a result of the intrapleural
instillation. Lymphoma is commonly associated with
fever,12 but the two lymphomas in this study did not
have tumour-induced fever. There was a significant
difference between success of pleurodesis at first
attempt in patients who reacted with early onset of
fever and those without fever reaction. The earlier
the onset of fever, the earlier pleurodesis was
achieved. The elevated levels of ESR, CRP and
leukocyte count mirrored the fever reaction, how-
ever there were no statistical differences in these
parameters on the outcome.
Very little on CRP levels or ESR rates in
pleurodesis can be found in the literature. A known
complication to pleurodesis is a pleural infection,
which occurs in up to 11 per cent of the cases.8 For
the clinician, it is useful to know that even high
temperatures and CRP levels are compatible with
the inflammatory reaction of the pleura, and that
such findings per se should not be treated with
antibiotics.
Factors which can predict the result of pleurod-
esis have been suggested to be pleural fluid glucose
level and pleural pH. Studies have, however, shown
contradictory results.13–16 One goal of the present
study was to evaluate whether the intensity of the
inflammatory reaction could predict a successful
pleurodesis. Unfortunately for this aspect of the
study, both the used agents are very effective. Talc
installation is successful in 90 per cent or more.8–
10,17 In the present study, overall success was 92 per
cent, with 81 per cent successful after first
installation. Thus, the ‘‘failure’’ group was small,
making statistical comparisons between the groups
difficult. Nevertheless, there is a clear tendency
that the small group of failures had a generally less
intense inflammatory reaction, which is compatible
with the idea that it is the inflammation that causes
the symphysis of the pleurae.
The use of anti-inflammatory drugs, especially
corticosteroids, is not uncommon in patients with
malignant diseases. Logically, such drugs could, by
suppressing the inflammation, have an inhibitory
impact on the sclerosing effect of installed drugs in
the pleura. This has also been shown to be true,18
which thus agrees well with our data.
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